Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial

Abstract Background Diabetes mellitus (DM) increases the risk of tuberculosis (TB) and will hamper global TB control due to the dramatic rise in type 2 DM in TB-endemic settings. In this trial, we will examine the efficacy and safety of TB preventive therapy against the development of TB disease in...

Full description

Bibliographic Details
Main Authors: Nyanda Elias Ntinginya, Lindsey te Brake, Issa Sabi, Nyasatu Chamba, Kajiru Kilonzo, Sweetness Laizer, Irene Andia-Biraro, Davis Kibirige, Andrew Peter Kyazze, Sandra Ninsiima, Julia A. Critchley, Renee Romeo, Josephine van de Maat, Willyhelmina Olomi, Lucy Mrema, David Magombola, Issakwisa Habakkuk Mwayula, Katrina Sharples, Philip C. Hill, Reinout van Crevel, On behalf of the PROTID Consortium
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Trials
Subjects:
Preventive treatment
Rifapentine
Isoniazid
Latent tuberculosis infection
Diabetes mellitus
Online Access:https://doi.org/10.1186/s13063-022-06296-8

Internet

https://doi.org/10.1186/s13063-022-06296-8

Similar Items